-
平臺(tái)編號(hào)：bio-69297
-
國(guó)際編號(hào)：CRL-5808?
-
細(xì)胞信息： NCI-H378
-
規(guī)格：Frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
NCI-H378
是否是腫瘤細(xì)胞：1
物種來(lái)源：人
細(xì)胞形態(tài)：上皮樣
年限：stage E
數(shù)量：大量
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)，多細(xì)胞聚集
ATCC Number：CRL-5808?
相關(guān)疾病：小細(xì)胞肺癌
運(yùn)輸方式：凍存運(yùn)輸
器官來(lái)源：肺
規(guī)格：0.1mg Designations: NCI-H378 [H378]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, multicell aggregates
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: lung
Tumor Stage: stage E
Disease: carcinoma; classic small cell lung cancer
Derived from metastatic site: pleural effusion
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Tumorigenic:Yes
Oncogene:c-kit +; L-myc +
DNA Profile (STR):Amelogenin: X
CSF1PO: 11,12
D13S317: 11
D16S539: 12
D5S818: 11,12
D7S820: 12
THO1: 6,9.3
TPOX: 8,9
vWA: 16,19
Age: 66 years
Gender: female
Ethnicity: Caucasian
Comments:This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from cells recovered from pleural effusion taken from a patient after chemotherapy.
NCI-H378 expresses elevated levels of the 4 biochemical markers of SCLC: neuron specific enolase, the brain isoenzyme of creatine kinase, L-dopa carboxylase and bombesin-like immunoreactivity.
The cells express the c-kit gene as well as the L-myc gene, and L-myc is amplified.
The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494
23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257
23106: Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933
23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
物種來(lái)源：人
細(xì)胞形態(tài)：上皮樣
年限：stage E
數(shù)量：大量
生長(zhǎng)狀態(tài)：懸浮生長(zhǎng)，多細(xì)胞聚集
ATCC Number：CRL-5808?
相關(guān)疾病：小細(xì)胞肺癌
運(yùn)輸方式：凍存運(yùn)輸
器官來(lái)源：肺
規(guī)格：0.1mg Designations: NCI-H378 [H378]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, multicell aggregates
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: lung
Tumor Stage: stage E
Disease: carcinoma; classic small cell lung cancer
Derived from metastatic site: pleural effusion
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Tumorigenic:Yes
Oncogene:c-kit +; L-myc +
DNA Profile (STR):Amelogenin: X
CSF1PO: 11,12
D13S317: 11
D16S539: 12
D5S818: 11,12
D7S820: 12
THO1: 6,9.3
TPOX: 8,9
vWA: 16,19
Age: 66 years
Gender: female
Ethnicity: Caucasian
Comments:This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from cells recovered from pleural effusion taken from a patient after chemotherapy.
NCI-H378 expresses elevated levels of the 4 biochemical markers of SCLC: neuron specific enolase, the brain isoenzyme of creatine kinase, L-dopa carboxylase and bombesin-like immunoreactivity.
The cells express the c-kit gene as well as the L-myc gene, and L-myc is amplified.
The cells express easily detectable levels of p53 mRNA compared to levels found in normal lung.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
References: 1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494
23056: Carney DN, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. Cancer Res. 45: 2913-2923, 1985. PubMed: 2985257
23106: Plummer H, et al. c-myc expression correlates with suppression of c-kit protooncogene expression in small cell lung cancer cell lines. Cancer Res. 53: 4337-4342, 1993. PubMed: 7689933
23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
